Edition:
United States

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

106.61USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$106.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
106,594
52-wk High
$139.79
52-wk Low
$87.75

Latest Key Developments (Source: Significant Developments)

Enrollment completed in Ligand's phase 2 trial of lgd-6972 in type 2 diabetes
Monday, 27 Feb 2017 09:00am EST 

Ligand Pharmaceuticals Inc : Enrollment completed in Ligand's phase 2 trial of lgd-6972 in type 2 diabetes .Ligand Pharmaceuticals Inc - company expects to report topline results in September 2017.  Full Article

Ligand Pharmaceuticals Q4 adjusted earnings per share $0.74
Thursday, 23 Feb 2017 04:01pm EST 

Ligand Pharmaceuticals Inc : Ligand reports fourth quarter and full year 2016 financial results . Q4 adjusted earnings per share $0.74 . Q4 GAAP loss per share $0.15 . Q4 revenue $38.2 million versus I/B/E/S view $40.3 million . Q4 earnings per share view $1.19 -- Thomson Reuters I/B/E/S . Ligand Pharmaceuticals says estimates 2017 core revenue to include royalties of about $87 million, material sales of about $23 million, contract payments of at least $20 million .Ligand Pharmaceuticals Inc says estimates that cash expenses for 2017 will be in range of $28 million to $30 million.  Full Article

Ligand expects revenue related to Captisol material sales to be unchanged
Wednesday, 18 Jan 2017 05:57pm EST 

Ligand Pharmaceuticals Inc : Ligand Pharmaceuticals - companies must adopt standard issued by FASB in may 2014 after january 1, 2017 and no later than january 1, 2018 . Ligand Pharmaceuticals Inc- company anticipates the standard will have a material impact on its consolidated financial statements - SEC filing . Ligand Pharmaceuticals Inc - expects revenue related to Captisol material sales to remain unchanged .Ligand Pharma-most significant impact from standards relates to accounting for revenues related to royalties, contingent "milestone" based payments.  Full Article

Ligand Pharmaceuticals sees q4 2016 revenue $39 million to $43 million
Thursday, 3 Nov 2016 04:01pm EDT 

Ligand Pharmaceuticals Inc : Q4 earnings per share view $1.37, revenue view $44.8 million -- Thomson Reuters I/B/E/S . Ligand reports third quarter 2016 financial results . Sees q4 adjusted earnings per share $1.29 to $1.36 . Q3 adjusted earnings per share $0.62 . Q3 gaap earnings per share $0.03 . Sees q4 2016 revenue $39 million to $43 million . Sees fy 2016 revenue $110 million to $114 million .Q3 earnings per share view $0.59 -- Thomson Reuters I/B/E/S.  Full Article

Ligand Q2 adjusted earnings per share $0.50
Thursday, 4 Aug 2016 08:00am EDT 

Ligand Pharmaceuticals Inc : Q2 adjusted earnings per share $0.50 . Q2 GAAP loss per share $0.28 . Q2 earnings per share view $0.40 -- Thomson Reuters I/B/E/S . Sees FY 2016 revenue $115 million to $119 million . Sees FY 2016 adjusted earnings per share $3.41 to $3.46 .FY2016 earnings per share view $3.30, revenue view $116.6 million -- Thomson Reuters I/B/E/S.  Full Article

Ligand announces licensing agreement with Nucorion Pharmaceuticals
Friday, 29 Jul 2016 08:30am EDT 

Ligand Pharmaceuticals Inc : Ligand announces multi-program LTP technology licensing agreement with nucorion pharmaceuticals . Newly-Formed Nucorion, co-founded by Ligand, to pursue a pipeline of LTP-based programs for China and other markets . Eligible to receive milestone payments as well as royalties ranging from 5% to 9% on net sales of products developed by Nucorion under agreement .Ligand announces multi-program LTP technology licensing agreement with Nucorion pharmaceuticals.  Full Article

Ligand enters into Omniab platform license agreement with Gilead Sciences
Friday, 8 Jul 2016 09:00am EDT 

Ligand Pharmaceuticals Inc : Ligand enters into Omniab® platform license agreement with Gilead Sciences . Gilead will be responsible for all costs related to programs .Ligand is eligible to receive annual platform access payments, milestone payments and royalties.  Full Article

Ligand Pharmaceuticals Inc gives FY 2016 and FY 2017 guidance
Wednesday, 4 May 2016 06:00am EDT 

Ligand Pharmaceuticals Inc:Says that including the effects of synthetic royalty acquisition from CorMatrix, Ligand now expects FY 2016 total revenues to be between $115 million and $119 million.Says this guidance assumes about $1 million of revenue from the CorMatrix assets in 2016.Projects FY 2016 adjusted EPS to be in the range of $3.41 to $3.46, which includes about $0.04 of incremental EPS contribution from the acquisition.Says for FY 2017, Ligand expects total revenues to exceed $160 million with adjusted EPS of more than $5.03.Says this guidance assumes about $2 million of revenue from the CorMatrix assets in 2017, and about $0.08 of incremental EPS contribution from the acquisition.  Full Article

Ligand Pharmaceuticals Inc receives FDA Approval of EVOMELA(tm) (melphalan) for Injection
Tuesday, 15 Mar 2016 09:00am EDT 

Ligand Pharmaceuticals Inc:Approval from the U.S. Food and Drug Administration (FDA) of EVOMELA(tm) (melphalan) for use in two indications: 1) as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with MM.  Full Article

Ligand Pharmaceuticals Inc enters into OmniAb® Platform License Agreement with Tizona Therapeutics
Tuesday, 2 Feb 2016 09:00am EST 

Ligand Pharmaceuticals Inc:Ligand enters into omniab® platform license agreement with tizona therapeutics.Says tizona will be responsible for all costs related to the program.Says has entered into a worldwide license agreement with tizona therapeutics, inc.Ligand will be eligible to receive annual platform access payments for each successful omniab antibody.  Full Article

More From Around the Web

BRIEF-Ligand Pharmaceuticals says retrophin announced update on regulatory pathway for late-stage product candidate sparsentan

* Ligand Pharmaceuticals says on March 1 retrophin announced update on regulatory pathway for late-stage product candidate sparsentan - sec filing